Results 21 to 30 of about 18,378,232 (237)

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. [PDF]

, 2021
BACKGROUND The hepatic venous pressure gradient (HVPG) is the standard for estimating portal pressure but requires expertise for interpretation.
Shanis, Zahil, Montalto, Michael, Le, Quang Huy, Han, Ling, Harsha Pokkalla, Goodman, Zachary, Afdhal, Nezam, Quang Huy Le, Chung, Chuhan, Jaime Bosch, Harrison, Stephen A, Zachary Goodman, Manal F. Abdelmalek, Arun J. Sanyal, Rockey, Don C, Don C. Rockey, Andrew H. Beck, Resnick, Murray, Ilan Wapinski, Zahil Shanis, Ling Han, Myers, Robert P, Michael Montalto, Nezam Afdhal, Carrasco-Zevallos, Oscar M, Shiffman, Mitchell L, Oscar M. Carrasco‐Zevallos, Stephen A. Harrison, Pokkalla, Harsha, Chuhan Chung, Mitchell L. Shiffman, Dinkar Juyal, Abdelmalek, Manal F, Wapinski, Ilan, Bosch, Jaime, Jia, Catherine, Catherine Jia, Juyal, Dinkar, Sanyal, Arun J, Robert P. Myers, Murray Resnick, Beck, Andrew H   +41 more
core   +2 more sources

Non-invasive tests for clinically significant portal hypertension after HCV cure [PDF]

, 2022
BACKGROUND & AIMS: Non-invasive tests (NIT)s for clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG] ≥10mmHg) have predominantly been studied in patients with active HCV-infection.
Fortea, Jose Ignacio, Luzko Scheid, Irina Sofia, Schwabl, Philipp, Conthe, Andrés, Zanetto, Alberto, Scheid, Irina Sofia Luzko, Baiges, Anna, García-Pagán, Juan Carlos, Russo, Francesco Paolo, A study by the Baveno Cooperation: an EASL consortium, Francque, Sven M, Villanueva, Càndid, Díez, Cristina, Yoshiji, Hitoshi, Jia, Jidong, Paolo Russo, Francesco, Hernández-Gea, Virginia, Tsochatzis, Emmanuel A., Francque, Sven, Abadía, Marta, Lens, Sabela, Mauro, Ezequiel, Pagan, Juan Carlos Garcia, Meyer, Elias L., Sofia Luzko Scheid, Irina, Bosch, Jaume, García Pagán, Juan Carlos, Tellez, Luis, Ibañez-Samaniego, Luis, Crespo, Gonzalo, Ignacio Fortea, José, Reiberger, Thomas, Escudé, Laia, Semmler, Georg, Hernandez-Évole, Helena, Mandorfer, Mattias, Puente, Ángela, Alvarado-Tapias, Edilmar, Bañares, Rafael, Forns, Xavier, Meyer, Elias L, Llop, Elba, Alvardo-Tapias, Edilmar, Tsochatzis, Emmanuel A   +43 more
core   +2 more sources

Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy

Portal Hypertension & Cirrhosis, 2022
Aims Patients with cirrhosis and clinically significant portal hypertension (CSPH) usually have concomitant secondary hypersplenism, and splenectomy (Spx) is an option for treating these patients in the Asia‐Pacific region.
Fuchen Liu, Xinggang Guo, Wenli Zhang, Minghao Zou, Jian Huang, Wei Dong, Jinmin Zhang, Xiuli Zhu, Zeya Pan, Wan Yee Lau, Weiping Zhou, Hui Liu   +11 more
doaj   +1 more source

EUS-based shear wave elastography of the spleen for detection of clinically significant portal hypertension [PDF]

iGIE
Ryan Law, Jerry Yung-Lun Chin
exaly   +2 more sources

Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. [PDF]

, 2021
PURPOSE To analyze the predictive value of ΔT1 of the liver and spleen as well as the extracellular volume fraction (ECV) of the spleen as noninvasive biomarkers for the determination of clinically significant portal hypertension (CSPH) on routine Gd ...
Berzigotti, Annalisa, Obmann, Verena Carola, Christe, Andreas, Heverhagen, Johannes Thomas, Catucci, Damiano, Guensch, Dominik Paul, Ebner, Lukas, Huber, Adrian Thomas, Fischer, Kady, Gräni, Christoph   +9 more
core   +2 more sources

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)” [PDF]

Clinical and Molecular Hepatology
Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi   +4 more
doaj   +2 more sources

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

Hepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman, Neehar Parikh, Dan J. Clauw, David A. Williams, Elliot B. Tapper   +4 more
wiley   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Hepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran, Charlotte Wilhelmina Wernberg, Mette Munk Lauridsen, Maria Kløjgaard Skytthe, Sofie Marchsteiner Bendixen, Frederik Tibert Larsen, Camilla Dalby Hansen, Lea Ladegaard Grønkjær, Majken Storm Siersbæk, Tina Di Caterino, Sönke Detlefsen, Holger Jon Møller, Lars Grøntved, Kim Ravnskjaer, Søren Kragh Moestrup, Maja Sofie Thiele, Aleksander Krag, Jonas Heilskov Graversen   +17 more
wiley   +1 more source